sign101
sign101
sign101
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Revised<br />
2011<br />
4 Pharmacological management<br />
The aim of asthma management is control of the disease. Complete control of asthma is defined as:<br />
no daytime symptoms<br />
no night-time awakening due to asthma<br />
no need for rescue medication<br />
no exacerbations<br />
no limitations on activity including exercise<br />
normal lung function (in practical terms FEv 1 and/or PEF>80% predicted or best).<br />
minimal side effects from medication.<br />
; Lung function measurements cannot be reliably used to guide asthma management in<br />
children under five years of age.<br />
In clinical practice patients may have different goals and may wish to balance the aims of<br />
asthma management against the potential side effects or inconvenience of taking medication<br />
necessary to achieve perfect control.<br />
A stepwise approach aims to abolish symptoms as soon as possible and to optimise peak flow<br />
by starting treatment at the level most likely to achieve this. Patients should start treatment at<br />
the step most appropriate to the initial severity of their asthma. The aim is to achieve early<br />
control and to maintain by stepping up treatment as necessary and stepping down when control<br />
is good (see figures 4, 5 and 6 for summaries of stepwise management in adults and children).<br />
; Before initiating a new drug therapy practitioners should check adherence with existing<br />
therapies (see section 9.2), inhaler technique (see section 5) and eliminate trigger factors<br />
(see section 3).<br />
Until May 2009 all doses of inhaled steroids in this section were referenced against beclometasone<br />
(BDP) given via CFC-MDIs (metered dose inhaler). As BDP CFC is now unavailable, the reference<br />
inhaled steroid will be the BDP-HFA product, which is available at the same dosage as BDP-<br />
CFC. Note that some BDP-HFA (hydrofluroalkane) products are more potent and all should be<br />
prescribed by brand (see Table 8b). Adjustments to doses will have to be made for other inhaler<br />
devices and other corticosteroid molecules (see section 4.2).<br />
In this and the following section, each recommendation has been graded and the supporting<br />
evidence assessed for adults and adolescents >12 years old, children 5-12 years, and children<br />
under 5 years. The evidence is less clear in children under two and the threshold for seeking<br />
an expert opinion should be lowest in these children.<br />
1 2 3 1 Adults and adolescents aged over 12<br />
2 Children aged 5-12 years<br />
3 Children under 5 years<br />
recommendation does not apply to this age group.<br />
4 PhArMAColoGiCAl MAnAGeMent<br />
37